Pasar al contenido principal

MECANISMOS MOLECULARES ASOCIADOS A FACTORES DE RIESGO Y RESILIENCIA EN NEURODEGENERACION. METABOLISMO LIPIDICO Y DINAMICA DE MEMBRANAS

PID2019-110401RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Non-invasive biomarkers for mild cognitive impairment and Alzheimer&apos, s disease

  • Botello-Marabotto, Marina Dolores
  • Calero, Miguel
  • Pastor, Ana B.
  • Medina, Miguel
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Alzheimer's disease is the most common type of dementia in the elderly. It is a progressive degenerative disorder that may begin to develop up to 15 years before clinical symptoms appear. The identification of early biomarkers is crucial to enable a prompt diagnosis and to start effective interventions. In this work, we conducted a metabolomic study using proton Nuclear Magnetic Resonance (1H NMR) spectroscopy in serum samples from patients with neuropathologically confirmed Alzheimer's disease (AD, n = 51), mild cognitive impairment (MCI, n = 27), and cognitively healthy controls (HC, n = 50) to search for metabolites that could be used as biomarkers. Patients and controls underwent yearly clinical follow-ups for up to six years. MCI group included samples from three subgroups of subjects with different disease progression rates. The first subgroup included subjects that remained clinically stable at the MCI stage during the period of study (stable MCI, S-MCI, n = 9). The second subgroup accounted for subjects which were diagnosed with MCI at the moment of blood extraction, but progressed to clinical dementia in subsequent years (MCI-to-dementia, MCI-D, n = 14). The last subgroup was composed of subjects that had been diagnosed as dementia for the first time at the moment of sample collection (incipient dementia, Incp-D, n = 4). Partial Least Square Discriminant Analysis (PLS-DA) models were developed. Three models were obtained, one to discriminate between AD and HC samples with high sensitivity (93.75%) and specificity (94.75%), another model to discriminate between AD and MCI samples (100% sensitivity and 82.35% specificity), and a last model to discriminate HC and MCI with lower sensitivity and specificity (67% and 50%). Differences within the MCI group were further studied in an attempt to determine those MCI subjects that could develop AD-type dementia in the future. The relative concentration of metabolites, and metabolic pathways were studied. Alterations in the pathways of alanine, aspartate and glutamate metabolism, pantothenate and CoA biosynthesis, and beta-alanine metabolism, were found when HC and MCI- D patients were compared. In contrast, no pathway was found disturbed in the comparison of S-MCI with HC groups. These results highlight the potential of 1H NMR metabolomics to support the diagnosis of dementia in a less invasive way, and set a starting point for the study of potential biomarkers to identify MCI or HC subjects at risk of developing AD in the future., Authors acknowledge the Spanish Government MICINN (PID2019-110401RB-100) , ISCIII (COHORTES CIBERBBN-CIBERNED) , and Queen Sofia Foundation. This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe. This study was also supported by Generalitat Valenciana (CIPROM/2021/007) . M. Botello-Marabotto acknowledges Generalitat Valenciana for her PhD grant (ACIF/2020) and Spanish Government for her PhD grant (FPU 2020) .
Docta Complutense
Publicación Artículo científico (JournalArticle)

TNAP and P2X7R: New Plasma Biomarkers for Alzheimer’s Disease

  • Aivar, Paloma
  • Bianchi, Carolina
  • Di Lauro, Caterina
  • Soria Tobar, Lucía
  • Álvarez Castelao, Beatriz
  • Calero, Miguel
  • Medina, Miguel
  • Díaz Hernández, Miguel
Over the last few years, intense research efforts have been made to anticipate or improve the diagnosis of Alzheimer’s disease by detecting blood biomarkers. However, the most promising blood biomarkers identified to date have some limitations, most of them related to the techniques required for their detection. Hence, new blood biomarkers should be identified to improve the diagnosis of AD, better discriminate between AD and mild cognitive impairment (MCI) and identify cognitively unimpaired (CU) older individuals at risk for progression to AD. Our previous studies demonstrated that both the purinergic receptor P2X7 and the tissue-nonspecific alkaline phosphatase ectoenzyme (TNAP) are upregulated in the brains of AD patients. Since both proteins are also present in plasma, we investigated whether plasma P2X7R and TNAP are altered in MCI and AD patients and, if so, their potential role as AD biomarkers. We found that AD but not MCI patients present increased plasma P2X7R levels. Nevertheless, TNAP plasma activity was increased in MCI patients and decreased in the AD group. ROC curve analysis indicated that measuring both parameters has a reasonable discriminating capability to diagnose MCI and AD conditions. In addition to confirming that individuals progressing to MCI have increased TNAP activity in plasma, longitudinal studies also revealed that CU individuals have lower plasma TNAP activity than stable controls. Thus, we propose that P2X7 and TNAP could serve as new plasma biomarkers for MCI and AD.